Observational Study of Kibow Biotics in Dialysis Patients

Completed

Conditions studied: Chronic Kidney Failure

In brief

A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing dialysis along with standardized care of treatment.

Key facts

Study ID

NCT01450670

Run by

Kibow Pharma

People needed

30

Starts

2011-05-01

Expected to finish

2012-07-01

Last updated by the study team

2019-08-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently on hemodialysis
• 18 to 75 years of age
• Willing to give informed consent
• Baseline serum creatinine >2.5 mg/dL

You may not qualify if…

• Pregnant or nursing women
• Refusal to sign the informed consent form
• Documented to have HIV/AIDS/Liver disease
• Active dependency on drugs or alcohol
• Currently on anticoagulant therapy

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.